Literature DB >> 26191168

MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2.

Hesheng Li1, Qinglei Sun1, Bing Han2, Xingquan Yu3, Baoguang Hu3, Sanyuan Hu4.   

Abstract

Deregulated microRNAs (miRNAs) have been shown to play important roles in cancer progression as a result of changes in expression of their target genes. In this study, we investigated the expression of miR-16b in eight hepatocellular carcinoma (HCC) cell lines, revealed the roles of miR-26b on hepatocellular carcinoma (HCC) cell proliferation, migration, and invasion, and confirmed that EphA2 is a direct target of miR-26b. The miR-26b expression was decreased and EphA2 expression was evaluated in HCC cell lines. Luciferase assays revealed that miR-26b inhibited EphA2 expression by targeting the 3'-untranslated region of EphA2 mRNA. Overexpression of miR-26b dramatically inhibited the proliferation, invasion, and migration of HCC cells by targeting EphA2. Moreover, miR-26b down-regulated c-Myc and CyclinD1 expression, which was reversed by overexpressed EphA2. Taken together, our data demonstrated the mechanism of miR-26b contributed to HCC progression and implicated that miR-26b's potential in HCC therapy.

Entities:  

Keywords:  EphA2; hepatocellular carcinoma; invasion; miR-26b; migration; proliferation

Mesh:

Substances:

Year:  2015        PMID: 26191168      PMCID: PMC4503040     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  41 in total

1.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Authors:  Masato Nishimura; Eun-Jung Jung; Maitri Y Shah; Chunhua Lu; Riccardo Spizzo; Masayoshi Shimizu; Hee Dong Han; Cristina Ivan; Simona Rossi; Xinna Zhang; Milena S Nicoloso; Sherry Y Wu; Maria Ines Almeida; Justin Bottsford-Miller; Chad V Pecot; Behrouz Zand; Koji Matsuo; Mian M Shahzad; Nicholas B Jennings; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; George A Calin
Journal:  Cancer Discov       Date:  2013-09-03       Impact factor: 39.397

2.  Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.

Authors:  Masashi Ishikawa; Ryo Miyahara; Makoto Sonobe; Marika Horiuchi; Toshi Mennju; Ei Nakayama; Masashi Kobayashi; Ryutaro Kikuchi; Jiro Kitamura; Naoto Imamura; Cheng-Long Huang; Hiroshi Date
Journal:  Lung Cancer       Date:  2012-01-10       Impact factor: 5.705

3.  Identification of c-MYC as a target of the APC pathway.

Authors:  T C He; A B Sparks; C Rago; H Hermeking; L Zawel; L T da Costa; P J Morin; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1998-09-04       Impact factor: 47.728

4.  Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival.

Authors:  Tao Li; Jikai Yin; Lijuan Yuan; Shouli Wang; Lin Yang; Xilin Du; Jianguo Lu
Journal:  Oncol Rep       Date:  2014-02-19       Impact factor: 3.906

5.  EphA2 overexpression promotes ovarian cancer growth.

Authors:  Chunhua Lu; Mian M K Shahzad; Hua Wang; Charles N Landen; Seung W Kim; Julie Allen; Alpa M Nick; Nicholas Jennings; Michael S Kinch; Menashe Bar-Eli; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2008-04-19       Impact factor: 4.742

6.  EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma.

Authors:  Xiang-Dan Cui; Mi-Jin Lee; Goung-Ran Yu; In-Hee Kim; Hee-Chul Yu; Eun-Young Song; Dae-Ghon Kim
Journal:  Int J Cancer       Date:  2010-02-15       Impact factor: 7.396

7.  MiR-141 targets ZEB2 to suppress HCC progression.

Authors:  Shi-Min Wu; Hong-Wu Ai; Ding-Yu Zhang; Xiao-Qun Han; Qin Pan; Feng-Ling Luo; Xiao-Lian Zhang
Journal:  Tumour Biol       Date:  2014-07-10

8.  Epithelial-mesenchymal transition regulated by EphA2 contributes to vasculogenic mimicry formation of head and neck squamous cell carcinoma.

Authors:  Wei Wang; Peng Lin; Baocun Sun; Shiwu Zhang; Wenjuan Cai; Chunrong Han; Li Li; Honghua Lu; Xiulan Zhao
Journal:  Biomed Res Int       Date:  2014-04-17       Impact factor: 3.411

9.  MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer.

Authors:  Jia Li; Xiangjie Kong; Junfeng Zhang; Qifeng Luo; Xiaoyu Li; Lin Fang
Journal:  Cancer Cell Int       Date:  2013-02-01       Impact factor: 5.722

10.  MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1.

Authors:  Ying Liu; Yi Ding; Jing Huang; Shuang Wang; Wen Ni; Jian Guan; Qisheng Li; Yuqin Zhang; Yanqing Ding; Bin Chen; Longhua Chen
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

View more
  18 in total

Review 1.  Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.

Authors:  Faisal Saeed Khan; Ijaz Ali; Ume Kalsoom Afridi; Muhammad Ishtiaq; Rashid Mehmood
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

2.  MicroRNA dysregulation in lung injury: the role of the miR-26a/EphA2 axis in regulation of endothelial permeability.

Authors:  Ryan J Good; Laura Hernandez-Lagunas; Ayed Allawzi; Joanne K Maltzahn; Christine U Vohwinkel; Arun K Upadhyay; Uday B Kompella; Konstantin G Birukov; Todd C Carpenter; Carmen C Sucharov; Eva Nozik-Grayck
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-07-19       Impact factor: 5.464

3.  MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.

Authors:  Lixia Wang; Jingna Su; Zhe Zhao; Yingying Hou; Xuyuan Yin; Nana Zheng; Xiuxia Zhou; Jingzhe Yan; Jun Xia; Zhiwei Wang
Journal:  Cell Cycle       Date:  2017-09-12       Impact factor: 4.534

4.  Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.

Authors:  Hao Wang; Wei Hou; Aldeb Perera; Carlee Bettler; Jordan R Beach; Xianzhong Ding; Jun Li; Mitchell F Denning; Asha Dhanarajan; Scott J Cotler; Cara Joyce; Jun Yin; Fowsiyo Ahmed; Lewis R Roberts; Wei Qiu
Journal:  Cell Rep       Date:  2021-02-23       Impact factor: 9.423

Review 5.  MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis.

Authors:  Adriana Fodor; Andrada Luciana Lazar; Cristina Buchman; Brandusa Tiperciuc; Olga Hilda Orasan; Angela Cozma
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

6.  Identification of the miRNA-mRNA regulatory network of small cell osteosarcoma based on RNA-seq.

Authors:  Lin Xie; Yedan Liao; Lida Shen; Fengdi Hu; Sunlin Yu; Yonghong Zhou; Ya Zhang; Yihao Yang; Dongqi Li; Minyan Ren; Zhongqin Yuan; Zuozhang Yang
Journal:  Oncotarget       Date:  2017-06-27

7.  A proposed method for the relative quantification of levels of circulating microRNAs in the plasma of gastric cancer patients.

Authors:  Mayra-Cecilia Suárez-Arriaga; Javier Torres; Margarita Camorlinga-Ponce; Alejandro Gómez-Delgado; Patricia Piña-Sánchez; Hilda-Alicia Valdez-Salazar; Rosa-María Ribas-Aparicio; Ezequiel M Fuentes-Pananá; Martha-Eugenia Ruiz-Tachiquín
Journal:  Oncol Lett       Date:  2017-03-07       Impact factor: 2.967

8.  TR4 nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression.

Authors:  Ren'an Jin; Hui Lin; Gonghui Li; Junjie Xu; Liang Shi; Chawnshang Chang; Xiujun Cai
Journal:  Cell Death Dis       Date:  2018-02-15       Impact factor: 8.469

9.  Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma.

Authors:  Yong Wang; Baocun Sun; Xiulan Zhao; Nan Zhao; Ran Sun; Dongwang Zhu; Yanhui Zhang; Yanlei Li; Qiang Gu; Xueyi Dong; Meili Wang; Jindan An
Journal:  Oncotarget       Date:  2016-04-26

10.  MicroRNA-26b inhibits tumor metastasis by targeting the KPNA2/c-jun pathway in human gastric cancer.

Authors:  Ming-Ming Tsai; Hsiang-Wei Huang; Chia-Siu Wang; Kam-Fai Lee; Chung-Ying Tsai; Pei-Hsuan Lu; Hsiang-Cheng Chi; Yang-Hsiang Lin; Liang-Mou Kuo; Kwang-Huei Lin
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.